A Phase 4, Open-label Study to Assess the Feasibility and Efficacy on Motor and Non-motor Symptoms of Switching From Pramipexole or Ropinirole to Rotigotine Transdermal Patch in Subjects With Advanced Idiopathic Parkinson's Disease
Condition: Advanced Idiopathic Parkinson's Disease
MeSH terms: Parkinson Disease
Intervention: Rotigotine
Intervention description: Rotigotine up to 16 mg / 24 hours, 4 weeks.
Intervention MeSH terms: Rotigotine
Phase: Phase 4
Study type: Interventional
Primary purpose: Treatment
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 87.0
Sex: All
Minimum age: 30 Years
Maximum age: 80 Years
Healthy volunteers: No
Keywords: Rotigotine; Neupro; Switch; Dopamine agonists

Summary:

      The purpose of this study is to assess the safety and feasibility of switching subjects with
      advanced Parkinson's Disease (PD) from Pramipexole or Ropinirole to Rotigotine and to assess
      the effects of Rotigotine on motor and non-motor symptoms of Parkinson's Disease in subjects
      switched from previous treatment with either Pramipexole or Ropinirole.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Subject has idiopathic Parkinson's Disease of more than 3 years duration, as defined
             by the cardinal sign, bradykinesia, plus the presence of at least 1 of the following:
             resting tremor, rigidity, impairment of postural reflexes and is without any other
             known or suspected cause of Parkinsonism

          -  Subject has motor fluctuations

          -  Subject is not satisfactorily controlled following the investigator´s assessment on a
             total daily dose of Pramipexole or Ropinirole

          -  Subject has sleep disturbance or early morning motor impairment

          -  Subject has experienced nocturia for at least 3 nights within 7 days prior to the
             Baseline Visit

          -  Subject is taking L-dopa in combination with Benserazide or Carbidopa and has been on
             a stable dose of L-dopa for at least 28 days prior to the Baseline Visit

        Exclusion Criteria:

          -  Subject has had therapy with Tolcapone or Budipine

          -  Subject is receiving therapy with one of the following drugs either concurrently or
             within 28 days prior to Baseline (Visit 2): alpha-methyl dopa, metoclopramide,
             reserpine, neuroleptics, monoamine oxidase A (MAO-A) inhibitors, methylphenidate, or
             amphetamine

          -  Subject has a history of symptomatic (not asymptomatic) orthostatic hypotension in the
             6 months prior to Baseline (Visit 2)

          -  Subject has a history of significant skin hypersensitivity to adhesive or other
             transdermal preparations, or recent unsolved contact dermatitis

          -  Subject has a history of seizures or stroke within 1 year, or a history of myocardial
             infarction within the last 6 months prior to enrollment

          -  Subject is pregnant or nursing, or is of childbearing potential but (i) not surgically
             sterile or (ii) not using adequate birth control methods (including at least 1 barrier
             method) or (iii) not sexually abstinent or (iv) not at least 2 years postmenopausal

          -  Subject has a previous diagnosis of narcolepsy, sleep apnea syndrome, restless legs
             syndrome, or periodic limb movement disorder